62020TJ0397_INF
Judgment of the General Court (Third Chamber) of 6 October 2021 –Allergan Holdings France v EUIPO – Dermavita Company (JUVEDERM)
(Case T‑397/20)
(EU trade mark – Revocation proceedings – EU word mark JUVEDERM – Genuine use of the mark – Use in connection with the goods in respect of which the mark is registered – Article 51(1)(a) of Regulation (EC) No 207/2009 (now Article 58(1)(a) of Regulation (EU) 2017/1001))
1.
EU trade mark – Lodging of application for EU trade mark – Identification of the goods or services concerned by the trade mark – Use of the general indications in the headings of the classes of the Nice classification – Scope
(Commission Regulation No 2868/95, Art. 1, Rule 2(1))
(see para. 35)
2.
EU trade mark – Surrender, revocation and invalidity – Causes of revocation – Absence of genuine use of a trade mark – Word mark JUVEDERM
(Council Regulation No 207/2009, Arts 51(1)(a) and 57(5))
(see paras 44, 45, 51-53, 56)
3.
EU trade mark – Definition and acquisition of the EU trade mark – Assessment of the registrability of a sign – EU rules only taken into account – Decisions of national authorities not binding EU bodies
(Council Regulation No 207/2009)
(see para. 58)
Re:
Action brought against the decision of the Fourth Board of Appeal of EUIPO of 14 April 2020 (Case R 877/2019-4), relating to revocation proceedings between Dermavita Company and Allergan Holdings France.
Operative part
The Court:
1.
Rejects the plea of inadmissibility;
2.
Dismisses the action;
3.
Orders Allergan Holdings France SAS to bear, in addition to its own costs, the costs incurred by the European Union Intellectual Property Office (EUIPO) and two-thirds of the costs incurred by Dermavita Company S.a.r.l. relating to the present proceedings;
4.
Orders Dermavita Company S.a.r.l. to bear a third of its own costs relating to the present proceedings.